Industry News
First enrolment for Pharmaxis Aridol COPD study
Drug developer Pharmaxis (ASX:PXS) has enrolled its first patient for the phase II clinical trial to assess the ability of Aridol to predict the usefulness of inhaled corticosteroids as a treatment of chronic obstructive pulmonary disease (COPD). [ + ]
Four unis to team on plant biotech project
Four Australian universities have made an unusual decision to form a 'virtual company', Meristomics, to commercialise discoveries from basic research in their jointly operated ARC Centre of Excellence for Integrative Legume Research (CILR). [ + ]
Narhex board ousts MD
Sydney anti-viral drug developer Narhex Life Sciences (ASX:NLS) has relocated its head office to Melbourne following the resignation of founder and managing director John Majewski. [ + ]
Biosignal granted two local patents
Sydney-based Biosignal (ASX:BOS) has been granted two additional Australian patents relating to its novel anti-bacterial technology. [ + ]
Novogen drug reduces cardiovascular risk, subsidiary to list on NASDAQ
Biopharmaceutical company Novogen's (ASX:NRT) cardiovascular drug trans NV-04 has shown a significant reduction in blood pressure and reduced arterial stiffness in a Phase Ib clinical trial. [ + ]
Resonance set for US pilot study
Resonance Health Group (ASX:RHT) has signed a memorandum of understanding with a US radiology service provider for a pilot study in preparation for the commercial launch of its FerriScan diagnostic test. [ + ]
Electronic nose sniffs out problems
An Australian-developed electronic nose, developed by former CSIRO/University of New South Wales scientists, now part of E-Nose, can instantly sniff out weak but unpleasant odours and generate an electronic fingerprint of the strength and quality of the smell.
[ + ]Avastra abandons BioWeld Tube clinical trials
Biomaterials company Avastra (ASX:AVS) is to abandon a clinical trial of its BioWeld Tube at Concord Repatriation and General Hospital, Sydney. [ + ]
Antisense pleased with animal study of eye treatment
Antisense Therapeutics (ASX:ANP) has claimed successful results from animal studies targeting the growth hormone receptor with an antisense drug, designed to reduce the growth of new blood vessels that can lead to two eye diseases which are major causes of blindness. [ + ]
Polartechnics CEO wants profits this year
After a turbulent year, Sydney-based Polartechnics (ASX:PLT) has seen a threefold increase in sales revenue for the 2004-05 financial year and is aiming to be profitable in the current year. [ + ]
Peptech signs manufacturing deal
Sydney antibody therapeutics developer Peptech (ASX:PTD) has signed an agreement with an unnamed biopharmaceuticals manufacturer to make its potent anti-inflammatory domain antibody (dAb) for preclinical and human clinical trials. [ + ]
CSIRO wins US patent for key RNAi vector
The legal mists swirling the issue of ownership of key patents to RNA-induced (RNAi) gene silencing are lifting, with the US Patent Office granting CSIRO a patent for its Hellsgate family of vectors for exploring and manipulating gene function in plants and animals. [ + ]
'Simpler' new NHMRC structure welcomed
Australia's medical research community has welcomed news of major changes to the nation's sole research funding agency, the National Health and Medical Research Council (NHMRC). [ + ]
Benitec speculation leads to speeding ticket
Licence discussions between RNAi specialist Benitec (ASX:BLT) and an undisclosed party caused Bentiec's share price to rise from $0.135 on September 8 to $0.17 on September 9, the company has told the ASX. [ + ]
CollTech raises $2.27m in placement
Western Australian collagen purification company CollTech (ASX:CAU) has raised $2.27 million after fees from its recent private placement and share purchase plan. [ + ]
